Nanotechnology Now - Press Release: Arrowhead to Present at Upcoming March Conferences

Home > Press > Arrowhead to Present at Upcoming March Conferences

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.

Arrowhead to Present at Upcoming March Conferences

Pasadena, CA | Posted on March 1st, 2016

2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting - Los Angeles, March 4-7, 2016

March 7, 9:45 a.m. PST - Stacey Melquist, Ph.D., Arrowhead senior scientist, and coauthors, will deliver a poster presentation titled, "Targeting Factor 12 (F12) with a Novel RNAi Delivery Platform As a Prophylactic Treatment for Hereditary Angioedema (HAE)"

Cowen and Company 36th Annual Healthcare Conference - Boston, March 7-9, 2016

March 7, 4:00 p.m. EST - Chris Anzalone, Ph.D., Arrowhead president and chief executive officer, will present a company overview

Barclays Global Healthcare Conference - Miami, March 15-17, 2016

March 17, 10:15 a.m. EST - Chris Anzalone, Ph.D., Arrowhead president and chief executive officer, will present a company overview

Webcast links and copies of presentation materials can be accessed by visiting the Events section of the company's website at ir.arrowheadresearch.com/events.cfm.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate™ delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic diseases, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit

ir.arrowheadresearch.com/alerts.cfm.

About ARC-520

Arrowhead's RNAi-based candidate ARC-520 is being investigated in the treatment of chronic HBV infection. The small interfering RNAs (siRNAs) in ARC-520 intervene at the mRNA level, upstream of the reverse transcription process where current standard of care nucleotide and nucleoside analogues act. Arrowhead is investigating ARC-520 specifically to determine if it can be used to achieve a functional cure, which is an immune clearant state characterized by hepatitis B s-antigen negative serum with or without seroconversion. Approximately 350-400 million people worldwide are chronically infected with the hepatitis B virus, which can lead to cirrhosis of the liver and is responsible for 80% of primary liver cancers globally. Arrowhead is currently conducting Phase 2b multiple dose and combination studies in chronic HBV patients. In clinical studies to date, the most common reported adverse events in all subjects completing treatment were upper respiratory infection and headache.

About ARC-F12

Arrowhead's RNAi-based candidate ARC-F12 is in preclinical development as a potential treatment for factor 12 (F12) mediated diseases. Arrowhead sees clear unmet need in hereditary angioedema (HAE) and thromboembolic diseases. The biology of factor 12 as part of the coagulation cascade and the kinin-kallikrein system suggest that its reduction through RNAi may present opportunities in both disease areas. The company is currently conducting studies in order to advance ARC-F12 into clinical trials.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Research Corporation.

For more information, please click here

Contacts:
Arrowhead Research Corporation
Vince Anzalone, 626-304-3400
CFA

Investor Relations:
The Trout Group
Chad Rubin, 646-378-2947

Media:
Russo Partners
Matt Middleman, 212-845-4272
M.D.